{"id":"71891529-15d7-46b9-bfac-cc204ec899e0","arxiv_id":"2412.11137","paper_version":1,"verdict":"CONDITIONAL","confidence":"HIGH","novelty_score":0.0,"correctness_risk":"low","formal_verification":"none","parameter_count":0,"one_line_summary":"A beginner-level review of in silico drug discovery methods, covering target identification, docking, ADMET prediction, molecular dynamics, and binding free energy approaches.","lead":"This preprint is a broad review of computer-based (in silico) methods used in drug discovery, from target identification through binding-energy calculations. It is aimed at beginners and summarizes common tools and workflows such as molecular docking, virtual screening, and molecular dynamics.","discovery_kind":"review","skeptic_critique":{"model":"deepseek-v4-flash","headline":"Factual errors in core method descriptions (MDCK/Papp, hERG 'antigen', thalidomide/cytosine) undercut the beginner-review claim; conditional acceptance should require correction.","rationale":"The reader's verdict is CONDITIONAL, and my stress-test does not move it. The paper is a review, so its central claim is educational reliability rather than novel discovery. The weakest point is the factual accuracy of the method descriptions, which is a load-bearing premise for a beginner-oriented review. I identified specific, checkable errors in the full text, not merely missing methodology: Section 6.1 misidentifies MDCK as a permeability coefficient, Section 6.5 describes hERG as an antigen, and Section 3.3.1 substitutes cytosine for TNF-α in the thalidomide example. Any one of these would teach incorrect science to the intended audience. The unsupported 'systematic review' label in the Conclusion is a related but separate issue: without a search protocol or inclusion criteria, the completeness claim is not reproducible, and the appended block of unrelated self-citations further weakens confidence in the reference selection. These are correctable defects, so the manuscript does not need rejection; it needs targeted corrections before the educational claim can be accepted. I therefore keep the reader's CONDITIONAL verdict and set agreement_with_reader to partial: the reader emphasized citation fidelity and the missing systematic method, while I emphasize concrete factual errors in the technical content.","tokens_in":47653,"tokens_out":9172,"duration_ms":80093,"concrete_test":"Have three independent computational chemists fact-check Sections 3.3.1, 6.1, and 6.5 against the cited references and standard pharmacology sources. Specifically: (1) confirm whether 'MDCK' is a cell line rather than an apparent permeability coefficient; (2) confirm whether hERG is correctly described as an antigen; (3) confirm whether thalidomide's target in erythema nodosum leprosum is TNF-α rather than cytosine. If any of these checks confirms an error, the manuscript must be corrected before the 'A-to-Z for beginners' claim is accepted; if all three come back clean, the factual-accuracy concern is withdrawn.","verdict_should_be":"UNCHANGED","load_bearing_attack":"The central claim is that this is a reliable beginner-oriented overview of in silico drug discovery, and that claim depends on the accuracy of the technical descriptions. The full text contains concrete factual errors in exactly the sections a beginner would use. Section 6.1 equates the 'apparent permeability coefficient' with 'MDCK', but MDCK is a cell line used in permeability assays, not a permeability coefficient. Section 6.5 calls the hERG potassium channel 'a vital antigen'; hERG is an ion channel/off-target, not an antigen. Section 3.3.1 says 'cytosine, found in high amounts in leprosy patients, is selectively inhibited by thalidomide'; the relevant mediator in erythema nodosum leprosum is TNF-α, not the nucleic acid base cytosine. In a review aimed at beginners, these are not cosmetic issues: they actively teach incorrect facts. The Conclusion's self-description as a 'systematic review' is unsupported by any search protocol or inclusion criteria, and the closing block of 18 unrelated self-citations reinforces that the reference selection was not disciplined. Together these points mean the educational claim is not yet supported. They are correctable, so a conditional verdict, not rejection, is appropriate.","agreement_with_reader":"partial"},"referee_report":{"model":"deepseek-v4-flash","summary":"This manuscript is a narrative, beginner-oriented review of in silico methods in drug discovery, covering artificial intelligence and machine learning, target identification (genomics, proteomics, transcriptomics, metabolomics, protein structure prediction), hit identification (drug repurposing, HTS, virtual screening, network pharmacology), hit-to-lead and lead optimization (QSAR, de novo design, FBDD), molecular docking (flexibility types, search methods, scoring functions, QM/MM, DFT), drug-likeness rules, ADMET prediction, molecular dynamics simulation workflows, and binding free energy estimation by MM-PB(GB)SA. The paper's stated goal is to give beginners an A-to-Z account of computational drug discovery with emphasis on target identification at the genetic or protein level, and it claims to have both performed a \"systematic review\" and \"computed\" a binding free energy in the course of the work.","tokens_in":47855,"tokens_out":4346,"duration_ms":37170,"significance":"If the technical descriptions were reliable, this would be a useful entry point for students entering computational drug discovery: the coverage is broad and mostly current, including AlphaFold, QM/MM docking, DFT applications, network pharmacology, and standard MD simulation practice. The paper ships no new derivations or quantitative predictions, so its value rests entirely on the accuracy and clarity of its pedagogical descriptions. The strengths are genuine: Section 7.1 gives a correct and usable step-by-step MD setup checklist, Section 8 presents the standard MM-PBSA/MM-GBSA equations faithfully, and the reference list is extensive, including the authors' own prior computational studies. However, the educational claim is currently not supported because several core method descriptions in sections a beginner would rely on contain concrete factual errors, and the self-described \"systematic\" methodology is not backed by any reproducible search protocol.","major_comments":[{"comment":"The sentence \"The in vitro gold standard for determining how effectively substances is absorbed into the body is known as the apparent permeability coefficient or MDCK\" conflates a cell line with a measured quantity. Madin-Darby canine kidney (MDCK) is a cell line used in permeability assays; the measured quantity is the apparent permeability coefficient (Papp). The same paragraph also lists \"Membrane Permeability (Caco2 and MDCK)\" as \"two representative qualities,\" which is wording a beginner will misread. This needs to be corrected to distinguish assay systems from the permeability coefficients they produce.","section":"§6.1 (Absorption)"},{"comment":"The text states that \"the hERG K+ channel is a vital antigen to consider early in drug development.\" hERG is a voltage-gated potassium ion channel and a well-known off-target whose blockade causes QT prolongation and cardiotoxicity; it is not an antigen. Describing it as an antigen teaches an incorrect concept in precisely the section where beginners learn why hERG screening matters.","section":"§6.5 (Toxicity)"},{"comment":"The statement that \"cytosine, found in high amounts in leprosy patients, is selectively inhibited by thalidomide\" is factually wrong. The relevant mechanism of thalidomide in erythema nodosum leprosum is inhibition of TNF-α production, not inhibition of the nucleic acid base cytosine. Because this is presented as the reason the FDA approved thalidomide for ENL in 1998, the error directly corrupts the pedagogical example of successful drug repurposing.","section":"§3.3.1 (Drug repurposing)"},{"comment":"Both the Introduction (\"the binding free energy is calculated in Section 8\") and the Conclusion (\"The binding free energy was then computed\") claim that a binding free energy calculation was performed in this work. Section 8 only reviews the MM-PB(GB)SA formalism and provides standard equations; no system, no trajectory, and no numerical ΔGbind result appears anywhere in the manuscript. These sentences should be rewritten to say that the methods were reviewed rather than that a calculation was executed.","section":"§1 and §9 (Introduction and Conclusion)"},{"comment":"The Conclusion characterizes the paper as \"This systematic review\" without providing any search protocol, database list, inclusion/exclusion criteria, or PRISMA-style documentation. As written, the manuscript is a narrative review with a selective reference set. Either add a reproducible methodology section to justify the term \"systematic,\" or re-label the paper as a narrative/educational review.","section":"§9 (Conclusion)"}],"minor_comments":[{"comment":"The abstract contains the typo \"approaches has merged\" (should be \"approaches have emerged\"), and the Conclusion contains the garbled phrase \"the following research works wing research works\" before reference [322]; both need copyediting.","section":"Abstract and §9"},{"comment":"The sentence \"When 3D structures are accessible through resources like the Protein Data Bank (PDB) and the EMDataBank for cryo-electron microscopy structures\" is grammatically incomplete and should be finished or merged with the following sentence.","section":"§3.1.6.1 (Known 3D Protein Structures)"},{"comment":"The numbered algorithm for an MD simulation is confusing: after listing step 2 as force calculation and step 3 as updating coordinates/velocities, the text says \"In step 2, the updated location and velocity are utilized as inputs, and in step 3, a new time step is generated,\" which reverses the natural roles of the two steps. Please renumber or rewrite for clarity.","section":"§7 (Molecular Dynamics Simulations)"},{"comment":"The word \"draggability\" appears in the sentence about considering the target's properties; this should be \"druggability.\"","section":"§3.3.3.2 (Structure-based virtual screening)"},{"comment":"The lock-and-key description is internally confusing: after stating that drug and receptor are viewed as immovable locks and keys, the next sentence says the model can explain modest conformational changes before and after binding, which is a property of the induced-fit picture. Please clarify which model does what.","section":"§4.1 (Fundamental concepts of molecular docking)"},{"comment":"Several reference entries contain the homoglyph \"hƩps\" instead of \"https\" (e.g., refs [1], [258], and others), and the Author Contributions list a contributor \"YAR\" who does not appear in the author list (likely a typo for \"TAR\"). These formatting issues should be fixed in revision.","section":"References and Author Contributions"}],"recommendation":"major_revision","confidential_remarks":"The block of 18 \"future reading\" references appended to the Conclusion (refs [322]–[339]) consists almost entirely of the authors' own publications on topics unrelated to the review's subject matter (clustering validation indices, metaheuristic optimization, image encryption, ontology learning). This has the appearance of citation inflation and is unlikely to serve the stated purpose of guiding beginners toward further reading in in silico drug discovery. I would suggest the editor ask the authors to remove or replace this block with genuinely related literature, and to reconsider whether the paper's fit with the journal's scope is adequate given its mostly introductory character."},"author_rebuttal":null,"desk_editor":{"model":"deepseek-v4-flash","letter":"Here's my take: this is a beginner-oriented review, not a research result, and its value is entirely pedagogical. As a map of the CADD pipeline—target ID, docking, virtual screening, ADMET, MD, MM-GBSA—it is mostly coherent and well-organized. The MD simulation setup section and the MM-GBSA equations are the strongest parts. The paper introduces no new methods or data, so its significance is limited to education and orientation. That is a legitimate contribution if the facts are right.\n\nThe facts are not all right, and they are wrong in exactly the places a beginner would copy. Section 6.1 calls MDCK an 'apparent permeability coefficient'; MDCK is a cell line. Section 6.5 calls the hERG potassium channel 'a vital antigen'; hERG is an ion channel and off-target. Section 3.3.1 says thalidomide 'selectively inhibits cytosine' in leprosy patients; the relevant mediator in erythema nodosum leprosum is TNF-α. These are not stylistic slips. In a teaching review, they are load-bearing errors.\n\nThe Conclusion also says 'the binding free energy was then computed,' but no computation appears anywhere in the paper; Section 8 is a description of methods. Calling the paper a 'systematic review' without any search protocol or inclusion criteria is an overclaim, and the closing block of 18 unrelated self-citations from the same group's optimization and clustering papers does not help. The abstract and body also have typos ('has merged,' 'wing research works'). None of this is fatal in the sense of sinking the whole enterprise, but it does mean the central claim—that this is a reliable beginner overview—is not yet supported.\n\nCredit where it is due: the broad structure is sensible, the standard references are mostly appropriate, and with corrections the paper could serve as a useful entry point for students. The errors are localized and fixable. What I would not do is let it through as is, and I would not cite it in its current form.\n\nRecommendation: this deserves a serious referee, not a desk rejection. Send it out with instructions that the referee should check every technical claim in Sections 3, 6, and 8 and require the self-citation block and the 'systematic review' claim to be addressed. If the authors clean up the factual errors and overclaims, the result is a usable teaching review. If they don't, it isn't.","headline":"A useful beginner map of the CADD pipeline whose teaching value is undercut by three concrete factual errors and an overclaimed conclusion; fixable, and worth refereeing on condition.","tokens_in":48370,"tokens_out":2752,"would_cite":false,"duration_ms":26157,"reading_group":"no","serious_thinker":"yes","would_accept_peer_review":true},"rs_alignment":null,"lean_confirmation":null,"pith_extraction":{"msc":[],"pacs":[],"model":"deepseek-v4-flash","headline":"This paper argues that in silico drug discovery is best understood as one continuous pipeline, from identifying a disease-linked gene to ranking compounds by binding free energy, and it maps every stage for a beginner.","keywords":["computer-aided drug design","molecular docking","artificial intelligence","molecular dynamics","MM-GBSA","drug target identification","virtual screening","ADMET prediction"],"falsifier":"A concrete check would be to run the paper's described MM-GBSA single-trajectory protocol on a benchmark set of protein-ligand complexes with measured binding affinities and see whether the computed relative rankings reproduce experiment; if they do not, the review's implicit assertion that this rescoring step improves hit ranking is contradicted.","tokens_in":47486,"feed_emoji":"🧬","tokens_out":13726,"duration_ms":104988,"temperature":0.7,"pith_summary":"The paper sets out to give a beginner a single readable route through computational drug discovery, from identifying a disease-related gene or protein to ranking candidate compounds by binding free energy. Its central claim is that in silico methods now span this entire A-to-Z process and that learning the pipeline helps researchers cut the time, cost, and attrition of experimental drug development. A sympathetic reader would take away a structured map of the field: omics-based target discovery, hit finding by repurposing, high-throughput and virtual screening, lead optimization, molecular docking, drug-likeness and ADMET filters, molecular dynamics, and MM-PBSA/MM-GBSA rescoring. The contribution is educational synthesis rather than a new experimental result, and its usefulness stands or falls on whether the described methods are represented faithfully.","feed_headline":"From gene to drug: one pipeline maps computer-aided discovery","feed_subtitle":"A beginner's review connects target identification, docking, ADMET, and binding-energy ranking into one workflow.","key_machinery":"The central object is the A-to-Z in silico drug discovery pipeline itself: a staged workflow that connects a disease-associated target to a ranked set of candidate compounds. Its load-bearing role is organizational, since each stage supplies a named computational mechanism, such as the Rule of Five physicochemical cutoffs for drug-likeness, docking scoring functions for pose ranking, ADMET prediction models for pharmacokinetic filtering, and the MM-PB(GB)SA free-energy formulas for rescoring. The pipeline carries the argument by showing that these otherwise separate techniques are steps in one sequence, so that the output of one stage is the input of the next.","core_discovery":"On the authors' own terms, the central claim is that computational methods have matured into a coherent, stage-by-stage pipeline for drug discovery and that this pipeline can be taught as a single narrative. The paper walks from target identification through genomics, proteomics, transcriptomics, metabolomics, and structure prediction; moves to hit discovery via drug repurposing, high-throughput screening, virtual screening, and network pharmacology; then covers hit-to-lead and lead optimization with QSAR, de novo design, and fragment-based design. It closes the pipeline with molecular docking, drug-likeness and ADMET prediction, molecular dynamics simulation, and MM-PB(GB)SA binding free energy calculations, arguing that each stage narrows the chemical space and feeds better candidates into the next. The implicit assertion is that a beginner who follows this sequence can understand how in silico methods accelerate and de-risk the drug development process.","pith_inferences":["An implication the paper leaves implicit is that the pipeline is modular: replacing any single stage with a newer method, such as a newer machine-learning scoring function, should not disrupt the rest of the workflow.","The paper asserts that AI can reduce drug-development attrition; a natural test that would give this claim quantitative support is a prospective comparison of AI-selected and conventionally selected candidates in early clinical studies.","The pipeline framing suggests a natural next step: turning each described stage into a hands-on tutorial with a small worked example, something the review itself leaves to the reader."],"forward_implications":["A beginner can follow one continuous workflow from a disease-associated gene to a shortlist of candidate compounds, rather than learning each method in isolation.","Applying drug-likeness and ADMET filters early should reduce the number of compounds that fail later because of poor absorption, metabolism, or toxicity.","Ligand- and structure-based virtual screening can shrink libraries of millions of compounds to a small set worth experimental testing, lowering the cost of high-throughput screening.","Rescoring docked poses with MM-PB(GB)SA should improve the ranking of hit compounds and feed more reliable candidates into in vitro validation.","AI and deep learning, including deep-learning protein structure prediction, are presented as making target identification and hit finding faster and cheaper than purely experimental approaches."],"supporting_citations":[{"why":"Defines the Rule of Five physicochemical criteria that the paper uses as the core of drug-likeness screening.","marker":"[253]"},{"why":"Supplies the two-way classification of virtual screening into ligand-based and structure-based methods and frames the ADMET discussion.","marker":"[108]"},{"why":"Provides the bridge between molecular docking and molecular dynamics that organizes Sections 4 and 7.","marker":"[196]"},{"why":"Gives the thermodynamic equations and state-function reasoning behind the binding free energy calculations in Section 8.","marker":"[314]"},{"why":"Originates the MM-PBSA continuum-solvent approach that Section 8 presents for rescoring docked poses.","marker":"[316]"},{"why":"Establishes the MM-PB(GB)SA methodology for combining molecular mechanics with continuum solvation in free energy estimates.","marker":"[317]"},{"why":"Supplies the deep-learning protein structure prediction method described as transforming modeling of proteins without homologous structures.","marker":"[70]"},{"why":"Underpins the target discovery and lead optimization narrative, including the reasons why drug candidates fail in development.","marker":"[29]"},{"why":"Provides the AI-in-drug-discovery context and the ADMET prediction tasks of absorption, distribution, and metabolism reviewed in Section 6.","marker":"[75]"}],"fun_headline_variants":["A-to-Z in silico drug discovery, all in one beginner review","From gene to drug: the full computational pipeline explained","Computer-aided drug discovery: a beginner's complete roadmap","One review covers every in silico step from target to lead","Decoding in silico drug discovery: a stage-by-stage guide"],"cache_read_input_tokens":3200,"weakest_assumption_plain":"The load-bearing premise is that the cited references and the paper's brief descriptions accurately represent how these in silico methods actually work in practice, and that the selection of topics and references is representative enough to justify calling the result a systematic review.","fun_headline_variants_meta":{"raw":{"variants":["A-to-Z in silico drug discovery, all in one beginner review","From gene to drug: the full computational pipeline explained","Computer-aided drug discovery: a beginner's complete roadmap","One review covers every in silico step from target to lead","Decoding in silico drug discovery: a stage-by-stage guide"]},"model":"deepseek-v4-flash","effort":"low","cost_usd":0.000184,"raw_usage":{"total_tokens":1308,"prompt_tokens":926,"completion_tokens":382,"prompt_tokens_details":{"cached_tokens":384},"prompt_cache_hit_tokens":384,"prompt_cache_miss_tokens":542,"completion_tokens_details":{"reasoning_tokens":296}},"tokens_in":542,"tokens_out":382,"duration_ms":4005,"temperature":1.0,"reasoning_tokens":296,"cache_read_input_tokens":384,"cache_creation_input_tokens":0},"cache_creation_input_tokens":0},"created_at":"2026-08-11T15:15:04.726758+00:00","model_set":{"reader":"deepseek-v4-flash"},"falsifier":"A concrete check would be to run the paper's described MM-GBSA single-trajectory protocol on a benchmark set of protein-ligand complexes with measured binding affinities and see whether the computed relative rankings reproduce experiment; if they do not, the review's implicit assertion that this rescoring step improves hit ranking is contradicted.","supporting_citations":[],"review_version":1}